Evidence map›Paper›PMID 41640161›Full record

ArticleProblemy endokrinologii2026

[The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice].

N Y Sviridenko, E V Ananicheva, V M Gershevich, Y O Grusha, K A Chepilev, A V Surov, V V Yurgel, K S Shchukin, E G Bessmertnaya, O A Bilevich

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

N Y SviridenkoEndocrinology Research Centre.
E V AnanichevaCity Clinical Hospital No. 1 Named After A.N. Kabanov; Clinical Ophthalmologic Hospital named after V.P. Vykhodtsev.
V M GershevichOmsk State Medical University.
Y O GrushaResearch Institute of Eye Diseases Named After M.M. Krasnov.
K A ChepilevClinical Ophthalmologic Hospital named after V.P. Vykhodtsev.
A V SurovOmsk State Medical University; Clinical Ophthalmologic Hospital named after V.P. Vykhodtsev.
V V YurgelCity Clinical Hospital No. 1 Named After A.N. Kabanov.
K S ShchukinClinical Ophthalmologic Hospital named after V.P. Vykhodtsev.
E G BessmertnayaEndocrinology Research Centre.
O A BilevichCity Clinical Hospital No. 1 Named After A.N. Kabanov; Omsk State Medical University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid eye disease (TED) is an autoimmune pathology of the orbital tissues associated with autoimmune thyroid disease, most commonly occurring with Graves' disease. The clinical presentation of TED is extremely diverse, ranging from mild orbital involvement to potentially vision-threatening optical neuropathy. Early diagnosis of the active phase of TED is crucial, as immunosuppressive therapy is effective only during this phase, while treatment for patients in the inactive phase consists only of rehabilitative surgery. High-dose intravenous glucocorticoids are the first-line treatment for patients with moderate to severe active TED. Glucocorticoids are widely used due to their anti-inflammatory and immunosuppressive properties, but about 20-30% of patients remain resistant to glucocorticoid treatment. One promising direction in the treatment of glucocorticoid-resistant TED is the use of monoclonal antibodies targeting specific antigen epitopes. We present a clinical case of tocilizumab treatment in severe glucocorticoid-resistant TED complicated by optic neuropathy.

Indexed as

Antibodies, Monoclonal, HumanizedGlucocorticoidsGraves OphthalmopathyOptic Nerve DiseasesDrug ResistanceHumansImmunosuppressive AgentsTreatment OutcomeAntibodies, Monoclonal, HumanizedGlucocorticoidsImmunosuppressive Agentstocilizumab

Identifiers

PMID41640161
PMCPMC12954422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.